Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · Real-Time Price · USD
0.470
+0.005 (1.08%)
Nov 20, 2024, 4:00 PM EST - Market closed
Azitra Employees
Azitra had 10 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
10
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$9,750
Profits / Employee
-$902,814
Market Cap
3.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 10 | 0 | - |
| Dec 31, 2021 | 10 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| China Pharma Holdings | 231 |
| Genetic Technologies | 55 |
| NovaBay Pharmaceuticals | 26 |
| Pasithea Therapeutics | 8 |
| Artelo Biosciences | 6 |
| Lixte Biotechnology Holdings | 4 |
| Titan Pharmaceuticals | 4 |
| Tharimmune | 3 |
AZTR News
- 8 days ago - Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates - PRNewsWire
- 23 days ago - Azitra to Present at BIO-Europe 2024 - Business Wire
- 5 weeks ago - Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Business Wire
- 2 months ago - Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire
- 2 months ago - Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - Business Wire
- 2 months ago - Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 3 months ago - Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Business Wire
- 3 months ago - Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Business Wire